IL157228A0 - Modified proteins, designer toxins, and methods of making thereof - Google Patents

Modified proteins, designer toxins, and methods of making thereof

Info

Publication number
IL157228A0
IL157228A0 IL15722802A IL15722802A IL157228A0 IL 157228 A0 IL157228 A0 IL 157228A0 IL 15722802 A IL15722802 A IL 15722802A IL 15722802 A IL15722802 A IL 15722802A IL 157228 A0 IL157228 A0 IL 157228A0
Authority
IL
Israel
Prior art keywords
making
methods
modified proteins
designer toxins
toxins
Prior art date
Application number
IL15722802A
Other languages
English (en)
Original Assignee
Res Dev Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Res Dev Foundation filed Critical Res Dev Foundation
Publication of IL157228A0 publication Critical patent/IL157228A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Botany (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
IL15722802A 2001-02-12 2002-02-12 Modified proteins, designer toxins, and methods of making thereof IL157228A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26840201P 2001-02-12 2001-02-12
PCT/US2002/004195 WO2002069886A2 (en) 2001-02-12 2002-02-12 Modified proteins, designer toxins, and methods of making thereof

Publications (1)

Publication Number Publication Date
IL157228A0 true IL157228A0 (en) 2004-02-19

Family

ID=23022845

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15722802A IL157228A0 (en) 2001-02-12 2002-02-12 Modified proteins, designer toxins, and methods of making thereof

Country Status (13)

Country Link
US (5) US7083957B2 (xx)
EP (1) EP1406644A4 (xx)
JP (1) JP2005514000A (xx)
KR (2) KR20080056315A (xx)
CN (1) CN100413885C (xx)
AU (1) AU2002306477B2 (xx)
CA (1) CA2438143C (xx)
IL (1) IL157228A0 (xx)
NO (1) NO20033548L (xx)
NZ (1) NZ527501A (xx)
RU (2) RU2305684C2 (xx)
WO (1) WO2002069886A2 (xx)
ZA (1) ZA200305980B (xx)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6750329B1 (en) * 1989-05-05 2004-06-15 Research Development Foundation Antibody delivery system for biological response modifiers
IE62496B1 (en) * 1990-04-19 1995-02-08 Res Dev Foundation Antibody conjugates for treatment of neoplastic disease
US8110218B2 (en) * 2000-11-30 2012-02-07 The Research Foundation Of State University Of New York Compositions and methods for less immunogenic protein-lipid complexes
ZA200305980B (en) 2001-02-12 2007-01-31 Res Dev Foundation Modified proteins, designer toxins, and methods of making thereof
EP1414471B1 (en) * 2001-07-17 2012-06-13 Research Development Foundation Therapeutic agents comprising pro-apoptotic proteins
US7461046B2 (en) * 2002-02-07 2008-12-02 The University Of Utah Research Foundation Method for creating and using a treatment protocol
AU2003275985A1 (en) * 2002-06-12 2003-12-31 Research Development Foundation Immunotoxin as a therapeutic agent and uses thereof
WO2004071420A2 (en) * 2003-02-05 2004-08-26 The Research Foundation Of State University Of New York Compositions and methods for less immunogenic protein formulations
US7351688B2 (en) * 2003-02-05 2008-04-01 The Research Foundation Of State University Of New York Compositions and methods for less immunogenic protein formulations
CA2534565C (en) * 2003-08-05 2012-06-19 The Research Foundation Of State University Of New York Reconstitution medium for protein and peptide formulations
US7622571B2 (en) * 2003-10-03 2009-11-24 The University Of Texas System, Board Of Regents Methods and compositions for Mycoplasma pneumoniae exotoxins
US8586046B2 (en) 2003-10-03 2013-11-19 Board Of Regents, The University Of Texas System Methods and compositions for mycoplasma pneumoniae exotoxins
WO2005052129A2 (en) 2003-11-25 2005-06-09 Anjin Corporation Diptheria toxin variant
JP2008526889A (ja) * 2005-01-10 2008-07-24 リサーチ ディベロップメント ファウンデーション 癌治療のための標的化キメラ分子
RU2393874C2 (ru) * 2005-02-01 2010-07-10 Рисерч Дивелопмент Фаундейшн Полипептиды с направленным действием
WO2006110132A1 (en) * 2005-04-07 2006-10-19 Board Of Regents, University Of Texas System Methods and compositions for mycoplasma pneumoniae exotoxins
US20090104185A1 (en) * 2005-04-07 2009-04-23 Joel Barry Baseman Methods and Compositions for Mycoplasma Toxins
EP1898939A2 (en) * 2005-06-29 2008-03-19 The Research Foundation of State of University Of New York at Buffalo Compositions and methods for less immunogenic pr0tein-lip1d complexes
CN100443503C (zh) * 2005-07-18 2008-12-17 四川大学华西医院 人源化ctla-4单链抗体与人穿孔素通道形成肽p34的重组免疫毒素
EP2332970B1 (en) * 2005-07-29 2015-12-23 The Government of the United States of America, as represented by the Secretary of Health and Human Services Mutated pseudomonas exotoxins with reduced antigenicity
WO2007021822A2 (en) * 2005-08-09 2007-02-22 The Research Foundation Of State Of University Of New York At Buffalo Compositions and methods of preparation of liposomal microparticulate il-12
US20070202593A1 (en) * 2006-02-27 2007-08-30 Research Development Foundation Cell-Targeted IKB and Methods for the Use Thereof
AU2007235463B2 (en) * 2006-03-30 2012-11-22 The Research Foundation Of State University Of New York Compositions of less immunogenic and long-circulating protein-lipid complexes
US7875288B2 (en) * 2006-03-30 2011-01-25 The Research Foundation Of State University Of New York Method for treating blood coagulation disorders
WO2007122511A2 (en) * 2006-04-21 2007-11-01 Mab-Factory Gmbh Antibody-rnase-conjugate
JP2010530895A (ja) * 2007-06-21 2010-09-16 アンジェリカ セラピューティックス，インク． 修飾毒素
WO2009110944A1 (en) * 2008-02-29 2009-09-11 Angelica Therapeutics, Inc. Modified toxins
US20100068151A1 (en) * 2008-03-11 2010-03-18 Rosenblum Michael G Multimodality molecular imaging with therapeutic conjugates
CN101671397B (zh) * 2008-10-09 2012-09-05 四川大学 抗EGFR单链抗体融合Gelonin重组免疫毒素及其制备方法与用途
KR101821343B1 (ko) 2010-03-01 2018-01-23 타우 쎄라퓨틱스 엘엘씨 암 진단 및 영상화
EP2755674A4 (en) * 2011-09-12 2015-04-08 Tau Therapeutics Llc ANTAGONISTS OF PRODUCTS OF THE HS-459642-UNIGEN CLUSTER TO AVOID PROLIFERATION, DEVELOPMENT, OR DIFFERENTIATION OF STEM CELLS WITH CANCER STEM CELLS
PL397167A1 (pl) 2011-11-28 2013-06-10 Adamed Spólka Z Ograniczona Odpowiedzialnoscia Przeciwnowotworowe bialko fuzyjne
EP4029937A1 (en) 2012-10-04 2022-07-20 Research Development Foundation Serine protease molecules and therapies
WO2014127211A1 (en) * 2013-02-15 2014-08-21 Research Development Foundation Deimmunized gelonin molecules and therapies
WO2014150600A2 (en) 2013-03-15 2014-09-25 Angelica Therapeutics, Inc. Modified toxins
US11020486B2 (en) 2013-11-05 2021-06-01 3M Innovative Properties Company Sesame oil based injection formulations
EP2871190A1 (en) * 2013-11-11 2015-05-13 ATLAB Pharma Antibody against GD2-O-acetylated ganglioside with pro-apoptotic activity
CN114853873A (zh) * 2015-06-11 2022-08-05 格纳西尼有限公司 经修饰的白细胞介素-7蛋白及其用途
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
EP3813863A4 (en) * 2018-06-28 2022-07-06 Dana Farber Cancer Institute, Inc. TARGETING MULTIPLE ANTIGENS BY MULTIPLEX CAR-T CELLS IN SOLID AND LIQUID MALIGNITIES
WO2020236939A2 (en) 2019-05-23 2020-11-26 Paradigm Diagnostics Tissue preparation using nuclease

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4263279A (en) 1975-08-19 1981-04-21 Yeda Research & Development Co. Ltd Pharmaceutically active compositions containing adriamycin and daunomycin
GB1564666A (en) 1978-05-31 1980-04-10 Ng Mun Hon Heterocomplexes of interferon with immunoglobulin and pharmaceutical compositions thereof
JPS5686121A (en) 1979-12-14 1981-07-13 Teijin Ltd Antitumor proten complex and its preparation
FR2504010B1 (fr) 1981-04-15 1985-10-25 Sanofi Sa Medicaments anticancereux contenant la chaine a de la ricine associee a un anticorps antimelanome et procede pour leur preparation
US4522918A (en) 1981-12-15 1985-06-11 Jeffery Schlom Process for producing monoclonal antibodies reactive with human breast cancer
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
EP0118365B1 (en) 1983-03-04 1990-08-29 Health Research, Inc. Monoclonal antibodies to human breast carcinoma cells and their use in diagnosis and therapy
FR2546756B1 (fr) 1983-06-03 1985-11-29 Centre Nat Rech Scient Nouveaux derives immunostimulants, leur preparation et leur application comme medicament
GB2148299B (en) 1983-09-01 1988-01-06 Hybritech Inc Antibody compositions of therapeutic agents having an extended serum half-life
US4666845A (en) 1983-12-16 1987-05-19 Sloan-Kettering Institute Monoclonal antibodies to ovarian, cervical and uterine human cancers and method of diagnosis
US4703004A (en) 1984-01-24 1987-10-27 Immunex Corporation Synthesis of protein with an identification peptide
US4894443A (en) 1984-02-08 1990-01-16 Cetus Corporation Toxin conjugates
US4753894A (en) 1984-02-08 1988-06-28 Cetus Corporation Monoclonal anti-human breast cancer antibodies
DE3586216T2 (de) 1984-05-01 1992-12-10 Ciba Corning Diagnostics Corp Brusttumorassoziiertes antigen und monoklonale antikoerper dazu.
FR2566271B1 (fr) 1984-06-20 1986-11-07 Sanofi Sa Nouveaux conjugues cytotoxiques utilisables en therapeutique et procede d'obtention
US4650674A (en) 1984-07-05 1987-03-17 Genentech, Inc. Synergistic cytotoxic composition
US4590071A (en) 1984-09-25 1986-05-20 Xoma Corporation Human melanoma specific immunotoxins
US4677064A (en) 1984-11-09 1987-06-30 Cetus Corporation Human tumor necrosis factor
US4708930A (en) 1984-11-09 1987-11-24 Coulter Corporation Monoclonal antibody to a human carcinoma tumor associated antigen
US5032521A (en) 1984-12-05 1991-07-16 The Salk Institute For Biological Studies Monoclonal antibody specific for a mammary tumor cell surface antigen
DE3585778D1 (de) 1984-12-05 1992-05-07 Salk Inst For Biological Studi Monoklonaler antikoerper, spezifisch fuer brustkrebszelloberflaechenantigen.
CA1339798C (en) 1985-02-01 1998-04-07 Alan N. Houghton Method for treatment of neuroectodermal malignancies and epithelial carcinomas in humans
EP0214995B1 (en) 1985-03-04 1990-12-27 Dana Farber Cancer Institute Immunotoxin and method of making
US4888415A (en) 1985-03-04 1989-12-19 Dana-Farber Cancer Institute, Inc. Gelonin immunotoxin
US6084073A (en) 1985-03-25 2000-07-04 Chiron Corporation Recombinant ricin toxin
JP2524586B2 (ja) 1985-06-26 1996-08-14 シタス コーポレイション ポリマ−接合を利用する医薬組成物用蛋白質の可溶化
US4870163A (en) 1985-08-29 1989-09-26 New York Blood Center, Inc. Preparation of pure human tumor necrosis factor and hybridomas producing monoclonal antibodies to human tumor necrosis factor
EP0222360A3 (en) 1985-11-12 1989-03-15 Biotherapeutics Inc. A method of producing a patient-specific cytotoxic reagent and composition
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US4962188A (en) 1985-12-06 1990-10-09 Cetus Corporation Recombinant ricin toxin A chain conjugates
DE3685485D1 (de) 1985-12-06 1992-07-02 Cetus Corp Anti-immuntoxine gegen menschlichen eierstockkrebs und verfahren zu deren verwendung.
US4831122A (en) 1986-01-09 1989-05-16 Regents Of The University Of Minnesota Radioimmunotoxins
JPS62190200A (ja) 1986-02-17 1987-08-20 Res Dev Corp Of Japan 抗腫瘍蛋白複合体およびその製造方法
US4894227A (en) 1986-08-01 1990-01-16 Cetus Corporation Composition of immunotoxins with interleukin-2
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4771128A (en) 1986-10-10 1988-09-13 Cetus Corporation Method of purifying toxin conjugates using hydrophobic interaction chromatography
US4861581A (en) 1986-12-05 1989-08-29 Cancer Biologics, Inc. Detection of necrotic malignant tissue and associated therapy
US5019368A (en) 1989-02-23 1991-05-28 Cancer Biologics, Inc. Detection of necrotic malignant tissue and associated therapy
US4963354A (en) 1987-01-21 1990-10-16 Genentech, Inc. Use of tumor necrosis factor (TNF) as an adjuvant
JPS63190200A (ja) 1987-02-03 1988-08-05 Toyota Motor Corp 電着塗装後処理方法
US4894225A (en) 1987-03-02 1990-01-16 Cetus Corporation Combination therapy using antitumor immunotoxins with tumor necrosis factor
NO881077L (no) 1987-03-11 1988-09-12 Univ Michigan Kjemo-radio-immuno-konjugater.
US4971792A (en) * 1987-03-27 1990-11-20 The Wistar Institute Monoclonal antibodies against glycolipid antigens
EP0623679B1 (en) 1987-05-21 2003-06-25 Micromet AG Targeted multifunctional proteins
US4863726A (en) 1987-05-29 1989-09-05 Cetus Corporation Combination therapy using immunotoxins with interleukin-2
US5095096A (en) 1987-05-29 1992-03-10 Sagami Chemical Research Center Fused protein comprising lymphotoxin
CA1341235C (en) 1987-07-24 2001-05-22 Randy R. Robinson Modular assembly of antibody genes, antibodies prepared thereby and use
EP0305967B1 (de) 1987-09-02 1993-05-05 Ciba-Geigy Ag Konjugate von Interferon alpha mit Immunglobulinen
US5017371A (en) 1988-01-06 1991-05-21 Amarillo Cell Culture Company, Incorporated Method for reducing side effects of cancer therapy
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
US4867962A (en) 1988-02-26 1989-09-19 Neorx Corporation Functionally specific antibodies
CA1329119C (en) 1988-03-29 1994-05-03 Milton David Goldenberg Cytotoxic therapy
IE62463B1 (en) 1988-07-07 1995-02-08 Res Dev Foundation Immunoconjugates for cancer diagnosis and therapy
US5135736A (en) * 1988-08-15 1992-08-04 Neorx Corporation Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
US5134075A (en) 1989-02-17 1992-07-28 Oncogen Limited Partnership Monoclonal antibody to novel antigen associated with human tumors
IE63847B1 (en) 1989-05-05 1995-06-14 Res Dev Foundation A novel antibody delivery system for biological response modifiers
US6750329B1 (en) * 1989-05-05 2004-06-15 Research Development Foundation Antibody delivery system for biological response modifiers
IE62496B1 (en) * 1990-04-19 1995-02-08 Res Dev Foundation Antibody conjugates for treatment of neoplastic disease
US6306626B1 (en) 1990-04-27 2001-10-23 Research Development Foundation Anti-IgM monoclonal antibodies and methods of their use
IE912716A1 (en) 1990-08-14 1992-02-26 Res Dev Foundation Protein Structure of the Plant Toxin Gelonin
US6099842A (en) 1990-12-03 2000-08-08 The United States Of America As Represented By The Department Of Health And Human Services Recombinant immunotoxin composed of a single chain antibody reacting with the human transferrin receptor and diptheria toxin
CA2331936C (en) * 1990-12-05 2007-07-31 Novozymes A/S Proteins with changed epitopes and methods for the production thereof
DE69123241T2 (de) 1990-12-14 1997-04-17 Cell Genesys Inc Chimärische ketten zur transduktion von rezeptorverbundenen signalwegen
RU2142015C1 (ru) 1991-09-06 1999-11-27 Рисерч Дивелопмент Фаундейшн Фрагмент днк, кодирующий белок гелонина, и способ его получения, вектор, обеспечивающий экспрессию белка гелонина, рекомбинантный штамм e.coli - продуцент белка гелонина
US5621083A (en) * 1991-11-04 1997-04-15 Xoma Corporation Immunotoxins comprising ribosome-inactivating proteins
US5837491A (en) 1991-11-04 1998-11-17 Xoma Corporation Polynucleotides encoding gelonin sequences
US6599505B1 (en) 1992-04-10 2003-07-29 Research Development Foundation Immunotoxins directed against CD33 related surface antigens
CA2162689C (en) 1993-05-12 2000-07-18 Marc D. Better Immunotoxins comprising gelonin and an antibody
US5851829A (en) 1993-07-16 1998-12-22 Dana-Farber Cancer Institute Method of intracellular binding of target molecules
IL112372A (en) 1994-02-07 2001-08-26 Res Dev Foundation Non-viral vector for the delivery of genetic information to cells
US5942230A (en) * 1994-05-06 1999-08-24 The United States Of America As Represented By The Department Of Health And Human Services Composition of immunotoxins and retinoids and use thereof
GB9506466D0 (en) 1994-08-26 1995-05-17 Prolifix Ltd Cell cycle regulated repressor and dna element
IL116559A (en) 1995-11-17 2005-11-20 Yissum Res Dev Co Chimeric protein consisting of a bacterial toxin and a myelin basic protein sequence
IL116436A (en) 1995-12-18 2006-12-31 Yissum Res Dev Co Fc?Á-PE CHIMERIC PROTEIN FOR TARGETED TREATMENT OF ALLERGY RESPONSES AND
US5851815A (en) 1996-03-19 1998-12-22 Idun Pharmaceuticals, Inc. MCH4 and MCH5, apoptotic proteases
IL118570A (en) 1996-06-04 2007-06-17 Shai Yarkoni Use of a chimeric protein that includes Met – GnRH in the preparation of a pharmaceutical preparation for the treatment of adenocarcinoma or patocarcinoma
NZ338013A (en) 1997-02-28 2001-05-25 Boehringer Ingelheim Pharma Use of TNFp-AIG (containing selected native elements of TNF-alpha promoter) for treating inflammatory diseases, such as rheumatoid arthritis
EP0893493A3 (de) 1997-07-21 2002-12-04 Aventis Pharma Deutschland GmbH Genetisch veränderte Zellen und deren Verwendung in der Prophylaxe oder Therapie von Erkrankungen
ATE294865T1 (de) * 1998-02-04 2005-05-15 Thromb X N V Identifizierung, produktion und verwendung von staphylokinase derivaten mit reduzierter immunogenizität und/oder reduzierter 'clearance'
KR20010086587A (ko) 1998-02-27 2001-09-13 데이비드 이. 프랭크하우저 유전자 요법에 의한 염증성 세포의 자기-조절된 고사
US6645490B2 (en) 1998-03-02 2003-11-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Chimeric proteins with cell-targeting specificity and apoptosis-inducing activities
US6140066A (en) 1998-03-24 2000-10-31 Lorberboum-Galski; Haya Methods of cancer diagnosis using a chimeric toxin
US20040009477A1 (en) 1998-04-03 2004-01-15 Invitrogen Corporation Methods for producing libraries of expressible gene sequences
AU754276B2 (en) 1998-04-03 2002-11-07 Invitrogen Corporation Methods for producing libraries of expressible gene sequences
WO1999051620A1 (en) 1998-04-03 1999-10-14 Invitrogen Corporation Libraries of expressible gene sequences
US6835550B1 (en) * 1998-04-15 2004-12-28 Genencor International, Inc. Mutant proteins having lower allergenic response in humans and methods for constructing, identifying and producing such proteins
CU22732A1 (es) * 1998-08-14 2002-02-28 Ct Ingenieria Genetica Biotech Mutantes de estreptoquinasa
EP1051432B1 (en) * 1998-12-08 2007-01-24 Biovation Limited Method for reducing immunogenicity of proteins
US6703020B1 (en) 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
AU2631501A (en) * 2000-01-06 2001-07-16 Monsanto Technology Llc Preparation of deallergenized proteins and permuteins
US20030186384A1 (en) 2000-04-22 2003-10-02 Stefan Barth Apoptotic agents
ZA200305980B (en) 2001-02-12 2007-01-31 Res Dev Foundation Modified proteins, designer toxins, and methods of making thereof
GB0116047D0 (en) 2001-06-29 2001-08-22 Implyx Ltd Peptide motif for therapy
EP1414471B1 (en) 2001-07-17 2012-06-13 Research Development Foundation Therapeutic agents comprising pro-apoptotic proteins
AU2003275985A1 (en) 2002-06-12 2003-12-31 Research Development Foundation Immunotoxin as a therapeutic agent and uses thereof

Also Published As

Publication number Publication date
KR20040022208A (ko) 2004-03-11
EP1406644A4 (en) 2005-03-16
ZA200305980B (en) 2007-01-31
US7083957B2 (en) 2006-08-01
NZ527501A (en) 2006-04-28
EP1406644A2 (en) 2004-04-14
RU2007112876A (ru) 2008-10-20
RU2432358C2 (ru) 2011-10-27
JP2005514000A (ja) 2005-05-19
US7943571B2 (en) 2011-05-17
US7741278B2 (en) 2010-06-22
KR20080056315A (ko) 2008-06-20
CA2438143A1 (en) 2002-09-12
US20100247518A1 (en) 2010-09-30
NO20033548L (no) 2003-10-10
WO2002069886A3 (en) 2004-01-22
CN1512888A (zh) 2004-07-14
US20070036780A1 (en) 2007-02-15
US8138311B2 (en) 2012-03-20
CN100413885C (zh) 2008-08-27
RU2305684C2 (ru) 2007-09-10
RU2003127678A (ru) 2005-01-20
US20110288275A1 (en) 2011-11-24
US7285635B2 (en) 2007-10-23
NO20033548D0 (no) 2003-08-11
CA2438143C (en) 2010-01-12
US20080292544A1 (en) 2008-11-27
US20030176331A1 (en) 2003-09-18
WO2002069886A2 (en) 2002-09-12
AU2002306477B2 (en) 2008-07-10

Similar Documents

Publication Publication Date Title
IL157228A0 (en) Modified proteins, designer toxins, and methods of making thereof
HK1205183A1 (en) High mannose proteins and methods of making high mannose proteins
ZA200305825B (en) Modified antibodies and methods of use
IL154212A0 (en) Method of producing proteins and means therefor
EP1451293A4 (en) NEW SULFURYLASE LUCIFERASE FUSION PROTEINS AND TEMPERATURE STABLE SULFURYLASE
EP1492554A4 (en) Spherical particles and process for their preparation and use
AU2002364528A8 (en) Bio-implant and method of making the same
EP1578912A4 (en) IL-13 MUTEIN PROTEINS, ANTIBODIES, COMPOSITIONS, METHODS AND USES
AU2002351239A8 (en) Antibody to latent membrane proteins and uses thereof
EP1529059A4 (en) LEPTIN PROTEIN, ANTI-ACID AND ANTIBODY FROM PIG
EP1441030A4 (en) METHOD OF PURIFYING RECOMBINANT FUSED PROTEIN AND PROTEIN PRODUCTION PROCESS USING THE PURIFICATION PROCESS
AU2002365269A8 (en) Mut-il-18 or mut-il-18r proteins, antibodies, compositions, methods and uses
IL162134A0 (en) Human cDNAs and proteins, and uses thereof
AU2002316162A1 (en) Method of increasing anti-neugc antibody levels in blood
EP1435996A4 (en) COMPOSITIONS COMPRISING MIXTURES OF THERAPEUTIC PROTEINS AND METHODS OF PREPARATION THEREOF
AU2002334781A1 (en) Novel human proteins, polynucleotides encoding them and methods of using the same
AU2003276844A8 (en) Formulations of modified antibodies and methods of making the same
AU2002341828A1 (en) Enhanced proteins and methods for their use
AU2002365215A8 (en) Methods of screening, determining, developing, and utilizing negative cross resistance toxins
AU2002303232A1 (en) Novel human proteins, polynucleotides encoding them and methods of using the same
AU2002257052A8 (en) Reg-like protein immunoglobulin derived proteins, compositions, methods and uses
AU2000280019A1 (en) Polypeptides, methods of making, and uses thereof
AU2002322404A8 (en) Novel human proteins, polynucleotides encoding them and methods of using the same
AU2002214598A1 (en) Claspin proteins and methods of use thereof
EP1549951A4 (en) SEMAPHORIN-LIKE PROTEINS AND METHODS OF USE THEREOF

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees